1.The Efficacy of Lamivudine in Korean Patients with Chronic Hepatitis B.
The Korean Journal of Hepatology 2005;11(1):25-30
No abstract available.
Antiviral Agents/*therapeutic use
;
Hepatitis B, Chronic/*drug therapy
;
Humans
;
Korea
;
Lamivudine/*therapeutic use
;
Treatment Outcome
4.The overview of the seminar on chronic hepatitis B.
Chinese Journal of Hepatology 2004;12(11):698-699
7.Current Antiviral Therapy for Chronic Hepatitis B.
Journal of Korean Medical Science 2004;19(4):489-494
During the past decade, major breakthroughs have been achieved in treatment of chronic hepatitis B. Currently, three therapeutic agents are approved for chronic hepatitis B: interferon-alpha, lamivudine and adefovir dipivoxil. In patients with HBeAgpositive chronic hepatitis B, all of these drugs achieve HBeAg loss (24-33%) and anti-HBe seroconversion (12-30%) rates that are superior to those observed in untreated controls. Interferon-alpha has several drawbacks, such as the parenteral administration and the development of frequent and potentially serious side effects. Lamivudine is a safe drug with rare and generally mild side effects. Lamivudine induces an initial virological remission in 70-90% of patients, but only 30-40% of patients remain in remission after the third year due to progressively increasing viral resistance. The main advantage of adefovir dipivoxil is the rare emergence of resistance, which has been identified in less than 2% of patients at 2 yr of treatment. Adefovir is also effective against lamivudine-resistant strains. This review will focus on the natural history and recently gained knowledge on the treatment of chronic hepatitis B.
Adenine/*analogs & derivatives/therapeutic use
;
Antiviral Agents/*therapeutic use
;
Hepatitis B/*drug therapy
;
Humans
;
Interferon-alpha/therapeutic use
;
Lamivudine/therapeutic use
;
Phosphonic Acids/therapeutic use
;
Reverse Transcriptase Inhibitors/therapeutic use
10.Comparative analysis of the efficacies of entecavir capsules and lamivudine in chronic hepatitis B patients.
Dao-zhen XU ; Hao-dong CAI ; Xiu-yun MA ; Yue-qi LI ; Xian-zhong LU ; Hai-ying YU ; Ai-min SUN ; Long-feng ZHAO ; Liao-yun ZHANG ; Xiao-hong GAO
Chinese Journal of Hepatology 2013;21(12):886-890
OBJECTIVETo investigate the efficacy profile of entecavir capsule (ETV) as a chronic hepatitis B therapy, as compared to lamivudine (LAM).
METHODSIn this multicenter, randomized, double-blind, parallel group evaluation of ETV, 232 subjects were administered a 96-week course of 0.5 mg/day ETV or 100 mg/day LAM. PCR measurement of hepatitis B virus (HBV) was conducted throughout the treatment course to determine achievement of complete virologic response (CVR; defined as less than 500 copies/ml of HBV DNA) or experience of virology rebound ( more than 500 copies/ml of HBV DNA after achievement of CVR).
RESULTSAfter week-48 of treatment, the ETV group showed a higher CVR rate (90.3% vs. LAM: 59.4%) and lower virology rebound rate (1.9% vs. LAM: 13.9%). After week-96 of treatment, the ETV group continued to have a higher CVR rate (86.0% vs. LAM: 71.4%), and virology rebound was experienced by significantly less subjects in the ETV group (1.2% vs. LAM: 11.9%, P = 0.005).
CONCLUSIONETV therapy can quickly and continuously suppress HBV replication in chronic hepatitis B patients, and has a lower resistance rate than LAM. Compared to LAM, ETV may be a superior long-term treatment choice for chronic hepatitis B.
Adult ; Antiviral Agents ; therapeutic use ; Double-Blind Method ; Female ; Guanine ; analogs & derivatives ; therapeutic use ; Hepatitis B, Chronic ; drug therapy ; Humans ; Lamivudine ; therapeutic use ; Male ; Young Adult
Result Analysis
Print
Save
E-mail